Serum MIF in Acute Kidney Injury

Macrophage Migration Inhibitory Factor in the Serum of Critically Ill Patients as an Early Marker for Acute Kidney Injury

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02352506

Enrollment

500

Registered

2015-02-02

Start date

2015-01-31

Completion date

2023-01-31

Last updated

2023-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury

Brief summary

Acute kidney injury (AKI) is a common complication in critical care patients. Currently no parameters are available for early prognosis of AKI. Macrophage migration inhibitory factor (MIF) has been associated with AKI in clinical studies. The aim of this study is to evaluate the time course of MIF concentrations in patients with AKI.

Interventions

OTHERBlood draw for measurement of MIF

Observational study, no intervention

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Exclusion criteria

* Age \< 18 years and \> 80 years * Patients with chronic dialysis * Patients with continuous hemodialysis, hemofiltration or hemodiafiltration within 4 weeks prior to the study * Patients with an expected length of ICU stay shorter than 3 days * Patients with a low probability of surviving the first 2 days after ICU admission * Pregnancy and nursing

Design outcomes

Primary

Measure	Time frame
Macrophage migration inhibitory factor	Up to 14 days

Secondary

Measure	Time frame
Serum creatinine	Up to 14 days

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026